DigitalDx Ventures

OXcan is a startup that focuses on early detection of lung cancer using advanced machine learning and liquid biopsy technologies. The company has developed an artificial intelligence-based healthcare platform that identifies cancer by analyzing targeted blood tests. This platform detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine screening. By evaluating multidimensional liquid biopsy results, which include DNA, proteins, epigenetic markers, and patient medical histories, OXcan enables healthcare providers to achieve early cancer detection and implement curative treatment strategies.

NOWDiagnostics develops and manufactures rapid diagnostic tests that use a single drop of blood, providing results within minutes. Its ADEXUSDx product line offers tests for common conditions like pregnancy, heart attack, and toxicology, empowering patients and caregivers with immediate healthcare insights.

Biotia, Inc. is a health technology company based in New York, founded in 2016. It specializes in developing software and laboratory technologies that leverage next-generation DNA sequencing and artificial intelligence to enhance infectious disease discovery and management. By providing tailored microbial surveillance, Biotia's innovative solutions enable clinicians and researchers to identify and mitigate pathogens effectively, thereby reducing hospital-acquired infections and improving patient outcomes. The company's technology empowers healthcare professionals to guide treatment decisions proactively, ultimately aiming to prevent illnesses before they occur.

GLX Analytix is a biotechnology company focused on transforming healthcare through the integration of proprietary blood biomarkers and artificial intelligence. The company aims to facilitate early diagnosis and continuous monitoring of chronic diseases, thereby empowering patients to manage their health more effectively. By providing tools that enable clinicians to monitor disease progression and predict flare-ups, GLX Analytix enhances treatment plans and improves patient outcomes. As an Industrial Partner to Harvard Medical/Wyss Diagnostic Accelerator and a recipient of the Roche Future of Healthcare Award, GLX Analytix is recognized for its potential to significantly impact patient care and quality of life on a global scale.

Trayt, Inc. is a patient-centric data analytics company based in Redwood City, California, focused on enhancing healthcare for patients with neuropsychiatric conditions. Founded in 2013, Trayt develops enterprise software tools that enable therapists and healthcare providers to measure the efficacy of treatments. The platform collects and analyzes a wide range of symptoms and health factors, providing real-time clinical insights that improve diagnosis and treatment accuracy. By facilitating the tracking, measurement, and sharing of behavioral and medical outcomes, Trayt aims to support clinicians in delivering coordinated and effective care.

Optina Diagnostics is a diagnostics company focusing on retinal imaging and artificial intelligence to provide non-invasive tests that detect signs of neurodegenerative and ocular diseases. By analyzing retinal images, it identifies biomarkers associated with Alzheimer's disease, as well as eye conditions like age-related macular degeneration and diabetic retinopathy, enabling clinicians to assess brain health and disease risk early. The platform aims to support timely diagnosis and treatment decisions with a simple eye exam.

NephroSant is an innovative diagnostic startup established by a team of physicians and experts in science, engineering, and clinical research, dedicated to enhancing global kidney health. The company has developed a urine-based diagnostic tool that enables the quantitative measurement of biomarkers crucial for the early detection and ongoing monitoring of kidney disease. This noninvasive tool is particularly valuable for physicians, as it aids in predicting and preventing the progression of kidney disease and facilitates the early detection of acute rejection in kidney transplant patients. Through their research-driven approach, NephroSant aims to significantly improve patient outcomes in kidney health.

Trayt, Inc. is a patient-centric data analytics company based in Redwood City, California, focused on enhancing healthcare for patients with neuropsychiatric conditions. Founded in 2013, Trayt develops enterprise software tools that enable therapists and healthcare providers to measure the efficacy of treatments. The platform collects and analyzes a wide range of symptoms and health factors, providing real-time clinical insights that improve diagnosis and treatment accuracy. By facilitating the tracking, measurement, and sharing of behavioral and medical outcomes, Trayt aims to support clinicians in delivering coordinated and effective care.

Delphi Diagnostics specializes in developing innovative diagnostic tools for breast cancer. Its flagship product is the Endocrine Activity Index (EAI) test, which measures endocrine activity in hormone receptor positive, HER2 negative breast cancer patients. This test aims to improve prognosis and treatment prediction, enabling personalized care.

AEENA Dx is a biotechnology company focused on developing a saliva-based platform for the detection of cancer and other diseases. The company specializes in biofluid-based molecular diagnostic tests that aim to enhance breast cancer screening and diagnosis. By improving the sensitivity and specificity of existing mammography programs, AEENA Dx seeks to make breast cancer detection more accurate, accessible, and affordable for women. This innovative approach allows patients to easily identify potential health issues related to breast cancer, enabling them to take timely measures for prevention and treatment.

Optina Diagnostics is a diagnostics company focusing on retinal imaging and artificial intelligence to provide non-invasive tests that detect signs of neurodegenerative and ocular diseases. By analyzing retinal images, it identifies biomarkers associated with Alzheimer's disease, as well as eye conditions like age-related macular degeneration and diabetic retinopathy, enabling clinicians to assess brain health and disease risk early. The platform aims to support timely diagnosis and treatment decisions with a simple eye exam.